| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| |
For the Three Months Ended
January 31,
|
| |
2020
|
|
2019
|
|
Net loss:
|
|
|
|
|
|
|
Cancer diagnostics
|
$
|
(1,790,646)
|
|
$
|
(1,804,354)
|
|
Cancer therapeutics
|
|
(825,929)
|
|
|
(2,487,285)
|
|
Patent licensing
|
|
-
|
|
|
(674,970)
|
|
Total
|
$
|
(2,616,575)
|
|
$
|
(4,966,609)
|
| |
|
|
|
|
|
|
Total operating costs and expenses
|
$
|
2,629,869
|
|
$
|
4,983,728
|
|
Less non-cash share-based compensation
|
|
(1,021,334)
|
|
|
(2,750,164)
|
|
Operating costs and expenses excluding non-cash
share-based compensation
|
$
|
1,608,535
|
|
$
|
2,233,564
|
| |
|
|
|
|
|
|
Operating costs and expenses excluding non-cash
share based compensation expense:
|
|
|
|
|
|
|
Cancer diagnostics
|
$
|
1,163,924
|
|
$
|
759,534
|
|
Cancer therapeutics
|
|
444,611
|
|
|
800,791
|
|
Patent licensing
|
|
-
|
|
|
673,239
|
|
Total
|
$
|
1,608,535
|
|
$
|
2,233,564
|
|
|
|
|
|
|
|
| |
|
| |
January 31,
2020
|
|
October 31,
2019
|
|
Total assets:
|
|
|
|
|
|
|
Cancer diagnostics
|
$
|
4,411,569
|
|
$
|
2,921,784
|
|
Cancer therapeutics
|
|
1,604,596
|
|
|
2,872,341
|
|
Patent licensing
|
|
147,786
|
|
|
499,568
|
|
Total
|
$
|
6,163,951
|
|
$
|
6,293,693
|
|